Aurora Cannabis Announces Private Offering of US $250 Million Of Convertible Senior Notes Due 2024 TSX: ACB | NYSE

Aurora Cannabis Announces Private Offering

of US $250 Million Of Convertible Senior Notes Due 2024

TSX: ACB | NYSE: ACB

EDMONTON, Jan. 16, 2019 /CNW/ - Aurora

Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) today announced

that it proposes to offer pursuant to a private placement US$250.0 million aggregate principal amount of convertible senior notes

due 2024 (the "notes"). Aurora also intends to grant to the initial purchasers of the notes an option to purchase up

to an additional US$37.5 million aggregate principal amount of notes.

Aurora expects to use the net proceeds from

the offering of the notes to support its Canadian and international expansion initiatives, for future acquisitions and for general

corporate purposes, including working capital requirements to continue the Company's accelerated growth.

The final terms of the notes will be determined

by Aurora and the initial purchasers. The notes will bear cash interest semi-annually at a fixed rate and be convertible by holders

into Aurora common shares at an initial conversion price higher than the closing common share price on the day of the pricing of

the notes. Aurora currently expects that upon conversion the notes will be settled in cash, shares of Aurora common shares or a

combination of cash and shares Aurora common shares, at Aurora's election. Aurora will be required to offer to repurchase the notes

upon the occurrence of customary events.

This announcement is neither an offer to sell

nor a solicitation of an offer to buy the notes or the common shares of Aurora into which the notes are convertible and shall not

constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

The notes and any common shares of Aurora issuable

upon conversion of the notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any

state securities laws, or qualified for distribution by prospectus in Canada, and may not be offered or sold in the United States

absent registration or an applicable exemption from such registration requirements, or sold in Canada absent an exemption from

the prospectus requirements of Canadian securities laws.

Headquartered in Edmonton, Alberta, Canada

with funded capacity in excess of 500,000 kg per annum and sales and operations in 22 countries across five continents, Aurora

is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across

every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis

and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora

has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate

leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale

production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are

designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.

Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf

Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to the Company's rapid organic

growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf,

CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses,

CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC Labs - Aurora is distinguished

by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic

partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:

HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private),

Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and

NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit

our investor website, investor.auroramj.com

Aurora Cannabis Inc.

Forward looking statements

This news release includes statements containing

certain "forward-looking information" and "forward looking statements" within the meaning of applicable securities

laws ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan",

"continue", "expect", "project", "intend", "believe", "anticipate",

"estimate", "may", "will", "potential", "proposed" and other similar words, or

statements that certain events or conditions "may" or "will" occur. Examples of such statements include statements

with respect to the anticipated pricing and completion of the notes offering; the planned use of proceeds from the notes offering;

and the final terms of the notes offering. The statements are based on the opinion and estimates of management at the date the

statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or

results to differ materially from those projected in the forward looking statements, including whether or not the Company will

offer the notes or consummate the offering, the final terms of the offering, prevailing market conditions, and the anticipated

principal amount of notes, which could differ based upon market conditions or for other reasons. The Company is under no obligation,

and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of

new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor its Regulation Services Provider

(as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this

SOURCE Aurora Cannabis Inc.

View original content: http://www.newswire.ca/en/releases/archive/January2019/16/c6581.html

For further information: For Media: Heather MacGregor, +1.416.509.5416,

heather.macgregor@auroramj.com; For Investors: Marc Lakmaaker, +1.647.269.5523, marc.lakmaaker@auroramj.com; Rob Kelly, +1.647.331.7228,

rob.kelly@auroramj.com; U.S. Investors: Phil Carlson / Elizabeth Barker, KCSA Strategic Communications, Phone: (212) 896-1233 /

(212) 896-1203, Email: pcarlson@kcsa.com / ebarker@kcsa.com

CO: Aurora Cannabis Inc.

CNW 16:31e 16-JAN-19